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1. Introduction 
Magnetic nanoparticles (MNP) have gained a lot of attention in biomedical and industrial 
applications due to their biocompatibility, easy of surface modification and magnetic 
properties. Magnetic nanoparticles can be utilized in versatile ways, very similar to those of 
nanoparticles in general. However, the magnetic properties of these particles add a new 
dimension where they can be manipulated upon application of an external magnetic field. 
This property opens up new applications where drugs that are attached to a magnetic 
particle to be targeted in the body using a magnetic field. Often, targeting is achieved by 
attaching a molecule that recognizes another molecule that is specific to the desired target 
area. This often requires a chemical recognition mechanism and does not succeed as 
designed. Therefore, magnetic nanoparticles can offer a solution to carry drugs to the 
desired areas in the body. 
Magnetic nanoparticles, although may contain other elements, are often iron oxides. Most 
common iron oxides are magnetite (Fe3O4), maghemite (γ-Fe2O3), hematite (α-Fe2O3) and 
geotite. Depending on the experimental conditions, one or more of the iron oxide phases 
may form. It is very important to carefully control the experimental conditions to ensure the 
presence of a single-phase. 
Frequently encountered iron oxide nanoparticles in applications are superparamagnetic. 
Superparamagnetism is a form of magnetism, which is observed with small ferromagnetic or 
ferrimagnetic nanoparticles. In small enough nanoparticles, magnetization can randomly flip 
direction of nanoparticle under the influence of temperature. However, the magnetic 
susceptibility of superparamagnetic nanoparticles is much larger than the paramagnetic ones. 
Superparamagnetism occurs in nanoparticles that have single-domain, i.e. composed of a 
single magnetic domain. In this condition, it is considered that the magnetization of the 
nanoparticles is a single-giant magnetic moment, the sum of all the individual magnetic 
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moments carried by the atoms of the nanoparticle. When an external magnetic field is applied 
to the superparamagnetic nanoparticles, they tend to align along the magnetic field, leading to 
a net magnetization. In the absence of an external magnetic field, however, the dipoles are 
randomly oriented and there is no net magnetization. The size dependence of magnetic 
properties of Fe3O4 nanoparticles synthesized from non-aqueous homogeneous solutions of 
polyols has been recently investigated (Caruntu et al., 2007). Out of the previously mentioned 
iron oxides, magnetite and maghemite are superparamagnetic and studies where these are 
used as magnetic nanoparticles will predominantly be focused in this summary.  
Recent toxicity studies on magnetic nanoparticles are summarized to show the 
biocompatibility of these particles. Research on targeting drugs using MNPs show to be 
very promising and some examples are given. Hyperthermia, which is a complementary 
treatment for tumors that uses magnetic field to increase temperature and cause cell death, 
can be achieved using MNPs and some recent advances in this field are presented. At the 
end, a table summaries different types of MNP matrixes used for drug delivery applications. 
2. Toxicity 
One of the main reasons that made magnetic nanoparticles interesting for biomedical 
applications is their biocompatibility. As these particles are being used as drug delivery 
vehicles, their cytotoxicity should be investigated in detail. These particles have been shown 
to have low toxicity in human body by several in vitro and in vivo studies.  
Ferric iron is normally transported by means of transferrin, which can bind the cell-surface 
localized transferrin receptor. Within the cell cytoplasm, the majority of the cytoplasmic iron 
pool is stored in specialized proteins called ferritin. Due to the physiological relevance of 
iron, MNPs were initially considered to be non-cytotoxic. MNPs can naturally be broken 
down resulting in the release of ferric iron which can then participate in the normal iron 
metabolism. It has, however, been recognized that the small size of MNPs might pose an 
additional hazard as the particles can reach high local concentrations within the cells and 
are generally more difficult to be efficiently cleared from the body (Rivera et al., 2010; Chan 
et al., 2002). Furthermore, free iron has been associated with the formation of free radicals, 
which would be particularly harmful to neural tissues already weakened by pathological 
processes (Winer et al., 2011). 
It is important to note that in almost all the studies, the toxicity is shown to increase 
significantly above a certain administration level. Although high loadings (>100 μg/mL) of 
MNPs cause cytotoxicity, the concentrations needed for drug delivery applications are often 
below the toxic level for suitably coated MNPs (Karlsson et al., 2008). 
Toxicity is often a result of serum proteins binding to the surface of the MNPs, altering the 
composition of the cell medium to which the cells are exposed (Mahmoudi et al., 2009). 
Coated nanoparticles induce lower toxicity not only due to the presence of the 
biocompatible coating, but also due to the lower adsorption sites for proteins, ions and other 
components in the medium (Mahmoudi et al., 2010). 
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Figure 1. (A) Schematic representation of the possible exchange/interaction scenarios at the 
bionanointerface at the cellular level. (B) Schematic drawing of the structure of protein–nanoparticle in 
blood plasma confirming the existence of various protein binding (e.g. an outerweakly interacting layer of 
protein (full red arrows) and a hard slowly exchanging corona of proteins (right) (Mahmoudi et al., 2011) 
Magnetite (Fe3O4) and maghemite (γ-Fe2O3) can show different cellular responses because of 
their ability to undergo oxidation/reduction reactions. In fact, magnetite has been shown to 
cause higher levels of oxidative DNA lesions (using comet assay) in A549 human lung 
epithelial cell line in the absence of decreased cell viability as compared to maghemite 
owing to its potential to undergo oxidation (Karlsson et al., 2009; Karlsson et al., 2008). 
One of the most sensitive parameters in toxicity is the surface coating of the nanoparticles. 
The degree of surface coverage has been postulated to be the main parameter in cellular 
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uptake as incomplete surface coverage was shown to promote opsonization and rapid 
endocytosis whereas fully coated MNPs escaped opsonization which, as a result, prolonged 
plasma half-life (Jung et al., 1995). The negatively charged uncoated MNPs have been shown 
to exhibit cytotoxicity above a certain threshold amount. Uncoated MNPs also have low 
solubilities which result in their precipitation in aqueous media impeding blood vessels in in 
vivo studies. In order to reduce the toxicity of MNPs, different coatings have been used. Häfeli 
at al. (Häfeli et al., 2009) have coated MNPs with polyethylene oxide (PEO) triblock 
copolymers (PEO-COOH-PEO) and found that the PEO tail block length inversely correlates 
with toxicity. PEO tail lengths above 2 kDa were suggested to be suitable for in vivo 
applications. Mahmoudi et al. (Mahmoudi et al., 2009) showed that uncoated particles induce 
greater toxicity than polyvinyl alcohol (PVA) coated magnetite particles. They also have 
shown that the toxicity of uncoated particles may significantly be reduced by substitution with 
surface-saturated uncoated particles. Coating maghemite particles with dimercaptosuccinic 
acid (DMSA) were shown to almost eliminate the toxicity of these particles (Auffan et al., 2006) 
by preventing direct contact between the particle and human dermal fibroblasts. However, in 
a different study using DMSA coated maghemite particles, a quantifiable model cell system is 
developed and showed that intercellular delivery of even moderate levels of MNPs may 
adversely affect cell function (Pisanic et al., 2007). Maghemite particles were coated with 
polyethylene imine (PEI)-g-polyethylene glycol (PEG) and their toxicity was compared with 
branched PEI coatings (Schweiger et al., 2011). Introduction of PEG was shown to have a 
shielding effect and resulted in lower toxicity Lee et al. (Lee et al., 2011) used ethylene glycol 
double layer stabilized maghemite nanoparticles and showed these to be non-toxic. PEG 
coating of magnetite particles also were shown to reduce the toxicity (Zhou et al., 2011). 
When MNPs are embedded in chitosan to obtain magnetic chitosan particles, they have 
shown to exhibit relatively low cytotoxicity (Park et al., 2005) due to complete coverage of 
MNPs with chitosan.  
Although dextran is a complex branched glucose that is often used in medical applications, 
dextran coated magnetite particles caused cell death as much as uncoated magnetite 
particles (Berry et al., 2003). Conversely, in a comparative study, uncoated magnetite, 
uncoated maghemite, dextran coated magnetite and dextran coated maghemite were 
investigated for cytotoxicity and neither of the samples exhibited cytotoxicity below 100 
mg/mL and the only samples that demonstrated genotoxicity was the dextran coated 
maghemite (Singh et al., 2012). In a more extensive study, Ding et al. (Ding et al., 2010) 
showed that the cytotoxicity of dextran hybridized magnetite nanoparticles is cell-specific. 
This result suggests that the related cells should be concerned for the cytotoxicity 
evaluation.  
A range of secondary surfactants around magnetic particles have been tested for toxicity in 
vivo. Citric and alginic acid surfactants were found to be significantly less toxic than starch, 
decanoic acid and PEG. This study shows the importance of optimizing surface coating to 
minimize toxicity (Kuznetsov et al., 1999).  
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In an in vivo study, albumin coated magnetite microspheres were shown to be well tolerated 
(Kuznetsov et al., 1999) Magnetite albumin microspheres bearing adriamycin (an anti-cancer 
drug) showed reduced toxicity to animal organs or cells compared to a single dose of 
adriamycin which reduces the side effects remarkably (Ma et al.,2000). However, in another 
study, albumin derivatized MNPs were found to cause membrane disruption, possibly due to 
the interaction of the protein with membrane fatty acids and phospholipids (Berry et al., 2003). 
Low cytotoxicity compared to uncoated magnetite particles was evaluated of Fe3O4–PLLA–
PEG–PLLA (PLLA: poly L-lactic acid) particles at the cellular level. They also create low 
genotoxic and immuntoxic at the molecular level. Acute toxicity tests showed quite a low 
toxicity which makes them have great potential for use in biomedical applications (Chen et 
al., 2012). Magnetite encapsulated in micelles of MPEG-PLGA (PLGA: poly (lactic-co-
glycolic acid) exhibited no cytoxicity (Ding et al., 2012). 
More recently, particle size as opposed to coating degree has been suggested to exert chief 
influence on the rates of uptake by macrophages (Raynal et al., 2004). In in vivo studies, 
MNPs of 50 nm (dextran coated) and 4 μm (polystyrene coated) were used and shown to be 
safe for intraocular applications (Raju et al., 2011). Oral, intravenous and intraperitoneal 
administration of MNPs of about 20 nm did not exhibit toxicity (Zefeng et al., 2005). MNPs 
with 1,6 hexanediamine were shown to be safe after being administered by intracerebral or 
intraarteral inoculation to rats (Muldoon et al., 2005). MNPs of 40 nm were shown to be non-
toxic to mES cells (Shundo et al., 2012). 
Under the application of magnetic field, MNPs were shown to exhibit higher toxicities 
which lead to cell death (Simioni et al., 2007; Bae et al., 2011). This is the basis of a tumor 
treatment, hyperthermia, which will be summarized in detail in the later sections. 
Despite such routine use of MNPs, the long-term effects and potential neurotoxicity have, as 
yet, not been evaluated extensively (Yildirimer et al., 2011).  
The ability to use magnetic nanoparticles in biomedical applications due to their low 
cytotoxicity, stirred a big interest in the scientific community to use these particles as drug 
carriers. In drug delivery, there are mainly two goals; first is the targeting of the drug to the 
desired area in the body to reduce the side effects to other organs and second is the 
controlled release of the drug to avoid the classical overdosing/underdosing cycle. Magnetic 
nanoparticles may provide a solution to both these goals. The coating around the magnetic 
nanoparticle is optimized to carry and release the drug in the desired fashion, like in the 
case of most nanoparticles. However, the unique property of these particles is that they are 
magnetic, allowing being manipulated using an external magnetic field. This forms the basis 
of magnetic targeting where the drug-carrying magnetic particle is directed to a specific area 
upon application of a magnetic field.  
3. Magnetic targeting 
In order to investigate the magnetic targeting in vitro, an experimental setup that models a 
branched artery supplying a tumor region with parameters close to the real system has been 
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constructed. The targeting of the particles was achieved and found to be dependent on the 
magnetic volume force in the branch point (Gitter et al., 2011). Using the same set-up, a 
novel quantitative targeting map that combines magnetic volume forces at characteristic 
points, the magnet position and quantitative data was constructed. Up to 97% of the 
nanoparticles were successfully targeted into the chosen branch (Gitter et al., 2011). 
A device for magnetically targeted drug delivery system (MT-DDS), which can allow to 
navigate and to accumulate the drug at the local diseased part inside the body by 
controlling to magnetic field strength and/or gradient generated by the superconducting 
magnets was developed. Mn-Zn ferrite particles are injected to an experimental apparatus as 
a vein model of the Y-shaped glass tubes using multiple bulk superconductor magnets. This 
is a basic technology for magnetically targeted drug delivery system that provides the drug 
navigation in the blood vessel of the circulatory organs system, which shows the usefulness 
of the medicine transportation methodology for MT-DDS (Mishima et al., 2007). 
To test seeding MNP in blood vessels and targeting the injected ones to these specific sites, 
experimental and computational models are constructed. To create strong and localized 
field gradients, microfluidic channels embedded with magnetic anchors were constructed 
using modified soft lithographic techniques to analyze the trapping process. Qualitative 
results from experimental investigations confirmed the legitimacy of the approach. It is 
demonstrated that capturing and aggregating magnetic microspheres at specified points in 
the vascular system is possible (Forbes et al., 2003). 
Locally targeted drug delivery using two magnetic sources was theoretically modeled and 
experimentally demonstrated as a new method for optimizing the delivery of magnetic 
carriers in high concentration to specific sites in the human body. Experimental results have 
demonstrated that capturing superparamagnetic beads of both micrometer and sub-
micrometer diameter at reasonably high concentrations is possible in flow conditions 
consistent with the dimensions and flow velocity occurring in the coronary artery in the 
human body. The same experiments performed with non-magnetic mesh resulted in no 
significant capture, indicating that the implant is responsible for providing the necessary 
magnetic field gradients and forces to capture the injected beads (Yellen et al., 2005). 
There are several in vivo studies on magnetic targeting. Magnetic chitosan nanoparticles, 
were successfully targeted to tumor tissue for photodynamic therapy, resulting in low 
accumulation in skin and hepatic tissue (Sun et al., 2009). 
Magnetic carbon nanotubes (MNT) with a layer of magnetite nanoparticles on their inner 
surface were prepared where the chemotherapeutic agents were incorporated into the pores. 
By using an externally placed magnet to guide the drug matrix to the regional lymph nodes, 
the MNTs are shown to be retained in the draining targeted lymph node for several days 
and continuously release chemotherapeutic drugs (Yang et al., 2008).  
In an in vitro study, magnetic poly(ethyl-2-cyanoacrylate) (PECA) nanoparticles containing 
anti-cancer drugs were shown to release drug and have magnetic mobility under external 
magnetic field (Yang et al., 2006). 
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Intra-caroid administration of polyethyleneimine (PEI) modified magnetic nanoparticles in 
conjunction with magnetic targeting resulted in 30 fold increase in tumor entrapment of 
particles compared to that seen with intravenous administration (Chertok et al., 2010).  
Magnetite-dextan composite particles were employed to deliver mitoxantrone in vivo. 
Mitoxantrone concentration in tumor tissue was found to be always significantly higher 
with magnetic targeting and the plasma iron concentrations fell after the application of the 
magnet, indicating the effectiveness of magnetic targeting (Krukemeyer et al., 2012). 
In another study, mitoxantrone was bound to superparamagnetic Fe3O4-nanoparticles and 
the drug loaded nanoparticles were given through the femoral artery close to the tumor. The 
magnetic nanoparticles were attracted to the tumors by a focused external magnetic field 
during the application. Results from HPLC-biodistribution experiments showed that 
magnetic drug targeting allows to enrich the therapeutic agent up to 50 times higher in the 
desired body compartment (i.e. the tumor region) compared to the commonly used systemic 
application (Alexiou et al., 2011).  
Magnetic nanoparticle seeds composed of magnetite carboxyl modified polydivinylbenzene 
and containing magnetite were studied in vitro for use as an implant in implant assisted-
magnetic drug targeting (IA-MDT). In the presence of a 70mT external magnetic field, the 
MNP seeds were captured first from a fluid stream passing through a 70% porous polymer 
scaff old that was designed to mimic capillary tissue. This is then used to capture magnetic 
drug carrier particles (MDCPs) with the same magnetic field (Mangual et al., 2011). 
Poly-[aniline-co-N-(1-one-butyric acid) aniline] (SPAnH) coated Fe3O4 particles with 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU). Bound-BCNU-3 could be concentrated at targeted 
sites in vitro and in vivo using an externally applied magnet. When applied to brain tumors, 
magnetic targeting was found to increase the concentration and retention of bound-BCNU-3 
(Hua et al., 2011). 
The accumulation of superparamagnetic nanoparticles with starch coating in gliosarcomas 
were enhanced by magnetic targeting and quantified by MR imaging (Chertok et al., 2008). 
PEG-modified cross linked starch coated magnetite particles for magnetic targeting studies 
in vivo. Selective, enhanced brain tumor targeting of intravenously administered PEG-MNPs 
was confirmed in a 9L-glioma rat model. Tumor targeting results, were promising and 
warranted both the further development of drug-loaded PEG-MNPs and concurrent 
optimization of the magnetic targeting strategy utilized (Cole et al., 2011).  
Super high-magnetization nanocarriers (SHMNCs) comprising of a magnetic Fe3O4 
(SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-onebutyric acid))aniline 
(SPAnH), which have a high drug loading capacity (27.1 wt%) of doxorubicin (DOX) were 
prepared. These nanocarriers enhanced the drug’s thermal stability and maximized the 
efficiency with which it is delivered by magnetic targeting therapy to MGH-U1 bladder 
cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the 
intracellular concentration of DOX (Hua et al., 2011).  
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Magnetic particles are also targeted to tumor area so tumors can be imaged. Iron oxides 
particles are often used as contrast agents for MRI. In fact, magnetite is an FDA approved 
contrast agent. In this summary, magnetic particles used for MRI will not be covered as the 
focus of this study is to make a comprehensive summary on magnetic drug delivery.  
As seen in the abovementioned studies, magnetic targeting is an efficient way to target 
drugs to the desired area, commonly to tumors. However, in some studies along with 
magnetic targeting, targeting ligands are also used. In the absence of magnetic targeting, 
targeting is achieved using ligands on drug carriers that specifically bind to receptors in the 
targeted area. A common ligand used for this purpose is folate (or folic acid). Folate has a 
high affinity for the folate receptor protein which is commonly expressed on the surface of 
many human cancers. If folate is tagged to a drug carrying nanoparticle, the folate binds to 
the folate receptor on the surface of cancer cell and the conjugate is uptaken via endocytosis, 
completing the targeted drug delivery. A schematic representation of a magnetic particle 
with targeting ligands is shown in Figure 2. 
 
Figure 2. (a) Schematic representation of the ‘‘core–shell’’ structure of MNPs and multi-functional 
surface decoration. MNPs consist of a magnetic iron oxide core coated with a biocompatible material 
(e.g. polysaccharide, lipid, protein, small silane linkers, etc.). Functional groups on the surface of 
coatings are often used to link ligands for molecular targeting, cellular internalization, optical imaging, 
enhanced plasma residence and/or therapy. The variety of moieties that decorate the MNP surface 
imparts the nanoparticle with its multi-functional, theranostic character. (b) Illustration of 
superparamagnetic MNP response to applied magnetic fields. MNPs comprise rotating crystals that 
align with the direction of an applied magnetic field. Crystal reorientation provides the high magnetic 
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susceptibility and saturation magnetization observed for this material. The circular dashed lines around 
the superparamagnetic nanoparticles on the left illustrate the randomization of their orientation, due to 
temperature effects, in the absence of a magnetic field. (Cole et al.2011).  
Magnetic nanocarriers were synthesized based on superparamagnetic iron oxide particles 
with biocompatible Pluronic F127 and poly(dl-lactic acid) (F127-PLA) copolymer chemically 
conjugated with folic acid (FA), carrying DOX. Magnetic particles were guided to targeted 
site by the aid of external magnetic field, and correspondingly the therapeutic efficacy of 
anti-tumor drug can be improved. These qualitative results were carried out with simply 
statistical analysis, which suggested that the dual targeting mechanisms can lead to better 
therapeutic results (Huang et al., 2012). 
Superparamagnetic iron oxide nanocrystals and DOX are co-encapsulated into 
PLGA/polymeric liposome core–shell nanocarriers withcholesterol with or without folate. 
The folate-targeting DOX loaded magnetic core–shell nanocarriers were shown to have 
better targeting effect to the Hela cells in vitro than their non-folate targeting counterparts 
(Wang et al., 2012). 
Thermosensitive magnetic liposomes with DPPC:cholesterol:DSPE-PEG2000:DSPE-
PEG2000-Folate (DPPC: Dipalmitoylphosphatidylcholine; DSPE: 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine) at 80:20:4.5:0.5 molar ratio were prepared containing DOX. This 
carrier, when physically targeted to tumor cells in culture by a permanent magnetic field 
yielded a substantial increase in cellular uptake of DOX as compared to Caelyx® (a 
commercially available liposomal doxorubicin preparation), non-magnetic folate-targeted 
liposomes (FolDox) and free DOX in folate receptor expressing tumor cell lines (KB and 
HeLa cells) ( Pradhan et al., 2010). 
Magnetic nanoparticles with mesoporous core-shell structure of silica were prepared and 
successfully modified with a fluorescent polymer chain as a labeling segment and folic acid 
as the cancer targeting moiety and loaded with a drug for directional release. The drug 
carrier was shown to be able to drill into the cell membranes and obtain a sustained release 
of the anticancer drug into the cytoplasm. The in vitro cellular uptake of the drug 
demonstrated that the drug-loaded nanocomposites could effectively target the tumor cells 
(Chen et al., 2010). 
Nanoparticles of Fe3O4 core with fluorescent SiO2 shell were synthesized and grafted with 
hyperbranched polyglycerol (HPG-grafted Fe3O4@SiO2 nanoparticles) conjugated with folic 
acid. Significant preferential uptake of the folic acid-conjugated nanoparticles by human 
ovarian carcinoma cells (SKOV-3) as compared to macrophages and fibroblasts were shown 
by in vitro studies (Wang et al., 2011). 
Magnetite nanoparticles are decorated through the adsorption of a polymeric layer 
(carboxymethly chitosan) around the particle surface and are conjugated with fluorescent 
dye, targeting ligand, and drug molecules for improvement of target specific diagnostic and 
possible therapeutics applications. Acrylic acid, folic acid, particles (Fe3O4-CMC-AA-FA) 
and DOX was loaded into the shell of the MNPs and release study was carried out at 
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different pH. The Fe3O4-CMC-AA-FA-DOX NPs showed a significant growth inhibition for 
HeLa cells in a dose dependent manner in comparison to NIH3T3 cells. This study indicates 
that Fe3O4-CMC-AA-FA is able to provide a single nanoscale construct, which is capable of 
tumor cell-targeting, imaging, and drug delivery functions. This is the first description of a 
chitosan based MNPs system possessing all of the above mentioned capabilities (Sahu et al., 
2012). 
Other ligands than folate have also been used for active targeting of nanoparticles. DOX on 
5-carboxylfluorescein (FAM) labeled AGKGTPSLETTP peptide (A54) coupled starch-coated 
iron oxide nanoparticles demonstrated the specificity of DOX-loaded A54-SIONs (SION: 
superparamagnetic iron oxide) to BEL-7402 cells in vitro. The microscopy images proved 
that DOX-loaded A54-SIONs were successfully targeted to tumor tissue of nude mice with 
an external magnetic field in vivo (Yang et al., 2009). 
Ligand-modified CPT-SAIO@SiO2 nanocarriers were used for the delivery of an anticancer 
agent (encapsulated camptothecin (CPT)). It was found that the modified nanocarriers 
showed reasonably high drug load efficiency for CPT and a high uptake rate by cancer  
cells overexpressing EGFR through clathrin-mediated endocytosis. The intracellular release 
of the CPT molecules via an external magnetic stimulus proved to be technically successful 
and ensured much higher therapeutic efficacy than that obtained with the free drug (Tung et 
al., 2011). 
Cetuximab-immuno micelles in which the anti-EGFR (Epidermal growth factor receptor) 
(EGFR), monoclonal antibody was linked to poly(ethylene glycol)-block-poly(ε-
caprolactone) (PEG–PCL) These micelles were loaded with DOX and Fe3O4 
superparamagnetic iron oxide. It was demonstrated that the immunomicelles inhibited cell 
proliferation more effectively than their nontargeting counterparts. Cetuximab-
immunomicelles bind more efficiently to the cancer cells that overexpress epidermal growth 
factor receptor, leading to a higher quantity of superparamagnetic iron oxide and DOX 
being transported into these cells (Liao et al., 2011). 
An anticancer drug was conjugated onto the PEGylated SPIO (SPIO: superparamagnetic 
iron oxide) nanocarriers via pH-sensitive bonds. Tumor-targeting ligands, cyclo(Arg-Gly-
Asp-D-Phe-Cys) (c(RGDfC)) peptides, and PET 64Cu chelators, macrocyclic 1,4,7-
triazacyclononane-N, N0, N00-triacetic acid (NOTA), were conjugated onto the distal ends 
of the PEG arms. cRGD-conjugated SPIO nanocarriers exhibited a higher level of cellular 
uptake than cRGD-free ones in vitro. These nanocarriers demonstrated promising properties 
for combined targeted anticancer drug delivery and PET/MRI dual-modality imaging of 
tumors (Yang et al., 2011). 
Polymeric liposomes (PEG/RGD-MPLs); composed of amphiphilic polymer octadecyl-
quaternized modified poly (γ-glutamic acid) (OQPGA), PEGylated OQPGA, RGD peptide 
grafted OQPGA and magnetic nanoparticles. It provided a possibility to responded to 
external permanent magnet with superparamagnetic characteristics, when was used for 
magnetic tissue targeting in vivo. The cell uptake results suggested that the PEG/RGDMPLs 
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(with RGD and magnetic particles) exhibited more drug cellular uptake than non RGD and 
non magnetism carriers in MCF-7 cells (Su et al., 2012). 
All these studies show that magnetic targeting is an efficient way to target drugs to tumor 
area. Coupled with active targeting using appropriate ligands, ligand-modified drug loaded 
magnetic nanoparticles, upon application of an external magnetic field provide excellent 
systems for effective drug targeting. Once targeting of magnetic particles to the desired area 
takes place, one of the most frequently used tumor treatments is hyperthermia. When 
magnetic nanoparticles are in the vicinity of the tumor and are subjected to an alternating 
magnetic field, dissipate heat and raise the temperature of the tumor, resulting in tumor cell 
death.  
4. Hyperthermia treatment 
Temperatures between 40°C and 45°C are generally being referred to as hyperthermia. 
Temperatures up to 42oC can render cancer cells more susceptible to the effect of irradiation 
and cause a certain degree of apoptosis, whereas temperatures >45°C are termed 
thermoablation and cause direct cell killing (necrosis) ( Elsherbini et al., 2011). 
In clinical applications of magnetic nanoparticle hyperthermia for cancer treatment it is very 
important to ensure a maximum damage to the tumor while protecting the normal tissue 
(Salloum et al., 2009). Although magnetic nanoparticle hyperthermia in cancer treatment 
holds great potential, it is severely limited by the fact that the anticipated heating 
distribution is difficult to control, and it leads to uneven and inadequate temperature 
elevation in tumor tissue. Transport of particles in tissue involves processes including 
extracellular transport of the carrier solution, transport of particles in the carrier solutions, 
and interaction between the particles and cell surface. The extracellular transport of 
nanoparticles in tumors is not well understood (Salloum et al., 2008). 
Hyperthermia is almost always used with other forms of cancer therapy, such as radiation 
therapy and chemotherapy. Hyperthermia may make some cancer cells more sensitive to 
radiation or harm other cancer cells that radiation cannot damage. When hyperthermia and 
radiation therapy are combined, they are often given within an hour of each other. 
Hyperthermia can also enhance the effects of certain anticancer drugs (Van der Zee, 2002; 
Wust et al., 2002). 
Numerous clinical trials have studied hyperthermia in combination with radiation therapy 
and/or chemotherapy. These studies have focused on the treatment of many types of cancer, 
including sarcoma, melanoma, and cancers of the head and neck, brain, lung, esophagus, 
breast, bladder, rectum, liver, appendix, cervix, and peritoneal lining (mesothelioma) (Falk 
et al., 2001; Feldman et al., 2003; Chang et al., 2001). Many of these studies, but not all, have 
shown a significant reduction in tumor size when hyperthermia is combined with other 
treatments. However, not all of these studies have shown increased survival in patients 
receiving the combined treatments (Van der Zee, 2002; Wust et al., 2002).Unique advantages 
of magnetic nanomaterials for hyperthermia based and combined therapies are 
schematically shown in Figure 3.  
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Figure 3. A schematic representation of some of the unique advantages of magnetic nanomaterials for 
hyperthermia-based therapy and controlled drug delivery (Kumar & Mohammad, 2011). 
Magnetic losses in an alternating magnetic field to be utilized for heating arise due to 
different processes of magnetization reversal in the particle system: (1) hysteresis, (2) Néel 
or Brown relaxation, and (3) frictional losses in viscous suspensions (Hergt et al., 2006).  
The magnetization of superparamagnetic nanoparticles can spontaneously change 
orientation under the influence of thermal energy. The magnetization oscillates between its 
two equilibrium positions. The typical time between two orientation changes is given by the 
Néel relaxation time	τ୒ = τ଴e ే౒ౡా౐, where τ0 is an attempt time with a value around 10−9-
10−10 seconds. 
In the absence of a magnetic field, magnetic nanoparticles in solution move randomly, a 
movement called Brownian motion. When magnetic field is applied to magnetic 
nanoparticles in a fluid, magnetic nanoparticles rotate and progressively align with the 
magnetic field due to the torque generated by the interaction of the magnetic field with the 
magnetization. The time taken for a magnetic nanoparticle to align with a small external 
magnetic field is given by the Brown relaxation time: τ୆ = ଷ஗୚୩ా୘, where η is the solvent 
viscosity. The delay between the magnetic field rotation and the magnetization rotation 
 
Magnetic Nanoparticles: Synthesis, Surface Modifications and Application in Drug Delivery 177 
leads to a hysteresis. The area of this hysteresis loop is dissipated in the environment as 
thermal energy, which used in magnetic hyperthermia. 
When an alternating magnetic field (AMF) is applied to a magnetic material, due to 
magnetic hysteresis, an energy is dissipated called the Specific Absorption Rate (SAR) and is 
expressed in W/g of nanoparticles. 
The SAR of a given material is given by SAR = Af, where A is the area of the hysteresis loop 
and f the alternation frequency of the magnetic field. A is expressed in J/g and is also called 
the "specific losses" of the material, hence SAR may also be referred to as Specific Loss 
Power (SLP) in some studies. 
The value of SAR estimated for the same material by several research groups may vary 
because it depends on several parameters like the physical and chemical properties of the 
carrier fluid, coating materials, frequency and amplitude of applied field, size and shape of 
Fe3O4 nanoparticles (Elsherbini et al., 2011). 
An optimized SAR distribution in terms of A is developed by optimizing an algorithm to 
inversely determine the optimum heating patterns induced by multiple nanoparticle 
injections (Salloum et al., 2009). For hyperthermia applications, high SAR values are 
required. One way to achieve this is to increase the magnetic field strength but the average 
magnetic field strength should be kept below 30 mT to avoid the formation of eddy currents, 
which can induce toxicity (Alphandéry et al., 2012). 
The study of SPA as a function of particle size shows that the average size and size 
distribution of the nanoparticles constituting a heating agent are central parameters for the 
design of efficient heating nanoparticles (Goya et al., 2008). 
Unfortunately a direct comparison of particle composition and size is very difficult to make. In 
one study multidomain ferrite particles were prepared and SAR data is compared with small 
magnetite particles with and without dextran coating. Large ferrite particles (200-400 nm) had 
considerably lower power absorption per mass than smaller particles of the same composition 
although both particle size distributions were relatively broad (Jordan et al., 1993). However 
particles with large sizes are shown not reach inner cell (Martín-Saavedra et al., 2010).  
By performing calorimetry measurements with Pluronic F127 coated Fe3O4 monodisperse 
particles it was shown that at a given frequency, heating rates of superparamagnetic 
particles are dependent on particle size, in agreement with earlier theoretical predictions. 
Results also indicate a broadening of SLP with sample polydispersity as predicted 
(Gonzales-Weimuller et al., 2009). 
Similarly, a mean particle diameter in the single domain size range (20–70 nm) combined 
with a small size distribution width are shown to enhance SLP (Hergt et al., 2007).  
Previous studies have shown a linear relationship between tissue iron concentration and 
heating rate in targeted magnetic hyperthermia treatment (Pardoe et al., 2003). A critical 
component of arterial embolization hyperthermia (AEH) is shown to be the concentration and 
distribution of ferromagnetic particles in the normal hepatic parenchyma (NHP), as well as in 
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the tumor tissue. If the distribution of particles in NHP is heterogeneous, with areas of high 
concentration, then unwanted areas of necrosis may result during AEH (Moroz et al., 2002). 
In another study, several types of magnetic iron oxide nanoparticles representative for 
different preparation methods (wet chemical precipitation, grinding, bacterial synthesis, 
magnetic size fractionation) are used for a comparative study (Hergt et al., 2006). 
Commercially available very small superparamagnetic particles are claimed to be 
suboptimal for effective tumor heating. In contrast, superparamagnetic magnetite 
nanoparticles were shown to be appropriate for inducing hyperthermia with radiofrequency 
to Ehrlich tumors (Elsherbini et al., 2011). 
No correlation was found between the magnetic moment of a single particle and SPA values 
for MNPs in the superparamagnetic regime. The optimum particle diameter is suggested to 
be near the critical size for the single- to multi-domain transition for Fe3O4 phase, although 
the relation between SPA mechanisms and incipient domain walls is still to be determined 
(Goya et al., 2008). 
When using magnetic nanoparticles as a heating source for magnetic particle hyperthermia 
it is of particular interest to know if the particles are free to move in the interstitial fluid or 
are fixed to the tumor tissue. The immobilization state determines the relaxation behaviour 
of the administered particles and thus their specific heating power (Dutz et al., 2011). If the 
particles are not able to rotate and a temperature increase due to Brown relaxation can be 
neglected. An investigation showed that carboxymethyl dextran coated magnetic particles 
are fixed rather strongly to the tumor tissue after injection into a tumor (Dutz et al., 2011). 
The effect of Néel relaxation on magnetic nanoparticles unable to move or rotate are studied 
and losses in linearly and circularly polarized fields are compared ( De Châtel et al., 2009). 
In frequencies lower than the Larmor frequency, linear polarization is found to be the better 
source of heat power, at high frequencies (beyond the Larmor frequency) circular 
polarization is preferable. If Néel relaxation in isotropic sample is the dominant mechanism, 
the technical complications of generating a circularly polarized field in difficult geometry 
need not be considered. 
In order to reach the required temperature with minimum particle concentration in tissue 
the specific heating power (SHP) of MNP should be as high as possible. The dependence of 
specific heating power of the size of superparamagnetic particles on the frequency and 
amplitude of the external alternating magnetic field is found to obey the predictions of 
relaxation theory. For small mean sizes (about 6 nm) the heating capability is negligibly 
small whereas larger particles deliver heating suitable for hyperthermia (Glöckl et al., 2006). 
Data on SLP commonly reported in the literature show remarkable scattering of the orders 
of magnitude of 10–100W g-1 for a field amplitude of 10 kA m-1 and frequency of about 400 
kHz (Hergt et al., 2006). 
In summary: 
1. The SLP of MNP must be considerably increased for achieving useful therapy 
temperatures in small tumors (at present smaller than 10mm diameter). 
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2. The main practical problem with MPH is an inadequate MNP supply to the tumor. For 
IT injection inhomogeneity of MNP distribution in tissue may lead to local temperature 
differences which do not allow for differentiation of hyperthermia and thermoablation. 
As a result of insufficient temperature enhancement in parts of the tumor there is a risk 
of proliferation of surviving tumor cells. 
3. For systemic supply of MNP (e.g. antibody targeting) the target enrichment with MNP 
must be considerably enhanced for achieving therapy temperature. In particular, the 
therapy of small targets (metastases below presently diagnostic limit) seems to be a 
questionable hope (Hergt et al., 2007). 
The specific loss power useful for hyperthermia is restricted by serious limitations of the 
alternating field amplitude and frequency. Large values of SLP of the order of some 
hundreds of W g−1 at 400 kHz and 10 kA m−1 are found for particles with mean size of about 
18 nm provided that the size distribution is sufficiently narrow. A very large value of SLP of 
nearly 1 kW g−1 is found for bacterial magnetosomes having a mean diameter of the 
magnetite crystals of about 35 nm (Hergt et al., 2006). 
MNPs modified with amino silane, which is commonly used in biomedicine, bacterial 
magnetosomes (BM) exhibit a better heating effect under AMF. Although both particles are 
found to enhance reduction in cell viability by hyperthermia using MNPs and 
magnetosomes of the same concentration, current of lower intensity is needed by BMs to 
produce a similar inhibitory effect in the tumor cell (Liu et al., 2012). 
When chains of magnetosomes, which are bound to each other by a filament made of 
proteins, are incubated in the presence of cancer cells and exposed to an alternating 
magnetic field of frequency 198 kHz and average magnetic field strength of 20 or 30 mT, 
they produce efficient inhibition of cancer cell proliferation. This behavior is explained by a 
high cellular internalization, a good stability in solution and a homogenous distribution of 
the magnetosome chains, which enables efficient heating (Alphandéry et al., 2012). 
When magnetosome chains are heated, the filament binding the magnetosomes together is 
denatured and individual magnetosomes are obtained which are prone to aggregation, are 
not stable in solution and do not produce efficient inhibition of cancer cell proliferation 
under application of an alternating magnetic field (Alphandéry et al., 2012).  
Poly(ethylene glycol) methyl ether methacrylate and dimethacrylate with iron oxide as 
implantable biomaterials. It was demonstrated that the temperature of the hydrogels can be 
controlled by changing the AMF strength so that the gels either reached hyperthermic (42–45 
°C) or thermoablative (60–63 °C) temperatures. The final temperature the hydrogel 
nanocomposites reach can be tailored to either one of these temperature ranges. The hydrogels 
were heated in an AMF, and the heating response was shown to be dependent on both iron 
oxide loading in the gels and the strength of the magnetic field (Meenach et al., 2010).  
Cationic magnetoliposome containing both magnetic fluid and the photosensitizer-based 
complex (CB:ZnPc-ML) were prepared using the thin lipid film method. This result shows 
that the application of light and AC magnetic field together can be much more effective than 
the each of the two treatments applied separately (Bolfarini et al., 2012). 
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Combined effect of magnetic hyperthermia and chemotherapy was evaluated using drug 
loaded PCPG magnetoliposomes. Thermosensitive drug release took place under the 
influence of magnetic field and this combined therapy was shown to be more efficient than 
either treatment alone (Kulshrestha et al., 2012). 
It was demonstrated that the temperature achieved with ferromagnetic MNPs was higher 
than that achieved with superparamagnetic MNPs, even with the same uptake amount into 
cells. This is due to heating efficiency differences between hysteresis loss and magnetic 
relaxation. Heat generation predominantly occurs by hysteresis loss rather than by magnetic 
relaxation. Heat produced by nanoparticles incorporated into cells and adsorbed on cell 
membranes should be critical for damaging cells, compared with heat produced from 
outside cells (Baba et al., 2012).  
According to some, the well-known iron oxide ferro fluids become undesirable because their 
iron atoms are poorly distinguishable from those of hemoglobin. A suggested solution is to 
use mixed-ferrites (MFe2O4 where M¼Co, Mn, Ni, Zn) to have a range of magnetic 
properties. These ferrites have attracted special attention because they save time, and 
because of their low inherent toxicity, ease of synthesis, physical and chemical stabilities and 
suitable magnetic properties (Sharifi et al., 2012).  
Giri et al. studied citrate coated ferrite particles below 100 nm sizes. Saturation 
magnetization is found to decrease for coated materials as magnetization is proportional to 
the amount of weight for the same magnetic material. The coercivity is found to be sufficient 
for hysteresis loss heating in hyperthermia. The magnetic hysteresis data indicate that these 
samples (coated) exhibit sufficient hysteresis losses to obtain the temperature required for 
the destruction of the tumorous cells. 
Ferrite particles were prepared in a chitosan matrix at varying ratios (Park et al., 2005). The 
time period needed for reaching hyperthermia shortened upon increase of chitosan ratio 
while the saturation magnetization decreases. Optimization of ferrite-chitosan ratio may be 
promising for hyperthermia applications. 
Co-Ti ferrite nanoparticles of 6-12 nm were shown to be suitable for hyperthermia 
applications (Ichiyanagia et al., 2012). Zn-Gd ferrite particles are suitable but if you cap them 
with poly (ethylene glycol) PEG, they are not useful (Yao et al., 2009). Co ferrite particles of 
7.5 nm copolymerized with poly(methacrylate) and poly(2-hydroxyethylmethacrylate) were 
shown to be suitable for hyperthermia (Hayashi et al., 2012). CoFe2O4 ferrite particles 
(ferromagnetic) were shown to be suitable for hyperthermia (Skumiel, 2006).  
Examining the heating produced by nanoparticles of various materials, barium-ferrite  
and cobalt-ferrite are unable to produce sufficient MFH heating, that from iron-cobalt occurs 
at a far too rapid rate to be safe, while fcc iron-platinum, magnetite, and maghemite are all 
capable of producing stable controlled heating. Iron-cobalt MNPs induce temperature 
changes that are too large, whereas barium-ferrite and cobalt-ferrite MNPs do not  
provide enough heat to treat a tumor. Simulations showed that magnetite, fcc iron-
platinum, and maghemite MNPs are well suited for MFH, making it possible to heat tumors 
above 41 °C while keeping the surrounding healthy tissue temperatures below this value 
(Kappiyoor et al., 2010). 
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The thermoreversible hydrogels (poloxamer, chitosan), which accommodated 20% w/v of 
the magnetic microparticles, proved to be inadequate. Alginate hydrogels, however, 
incorporated 10% w/v of the magnetic microparticles, and the external gelation led to  
strong implants localizing to the tumor periphery, whereas internal gelation failed in situ. 
The organogel formulations, which consisted of precipitating polymers dissolved in  
single organic solvents, displayed various microstructures. A 8% poly(ethylene-vinyl 
alcohol) in DMSO (DMSO: Dimethyl sulfoxide) containing 40% w/v of magnetic 
microparticles formed the most suitable implants in terms of tumor casting and heat 
delivery (Le Renard et al., 2010).  
Cell culture experiments showed that, by adjusting the amount of magnetic microspheres 
MMS and the time of exposure to AMF, heat treatments of mild to very high intensities 
could be achieved using maghemite nanoparticles embedded in mesoporous silica matrix 
(Martín-Saavedra et al., 2010). The heating effect of iron containing multi walled carbon 
nanotubes of 10-40 nm were studied and shown to be suitable (Krupskaya et al., 2009). 
Several magnetic fluids are shown to be suitable for hyperthermia application.  
In a comparative study, 16 commercial magnetic fluids are investigated and most suitable 
ones are distinguished (Kallumadil et al., 2009). Magnetite microcapsules of 20-30 μm 
embedded in agar phantom exhibited heat generation under an alternating magnetic field 
(Miyazaki et al., 2012). Magnetite nanoparticles of 10 nm in an aerogel matrix are potential 
hyperthermia agents where the aerogel matrix can be used for drug loading for combined 
therapy (Lee et al., 2012). 
As can be seen from the aforementioned studies, although there is not a clear definition for 
an ideal magnetic material for hyperthermia, there are several materials that can be 
employed, depending on the particular situation. Combined therapies of drug delivery and 
hyperthermia are promising future outlooks in this field. 
Magnetic Drug Carriers 
Being potential candidates for drug delivery due to their low toxicity and ability to be 
targeted, magnetic particles are often coated to stabilize them against precipitation, ensure 
their low cytotoxicity and to carry the drug in a matrix.  
In in vivo applications SPION particles should be coated to prevent the drug  
molecule conjugations and to limit interactions with non-targeted cell sides, to prevent 
particle agglomeration and for enhanced drug loading and release. Different approaches in 
SPION coating resulting different assembly of polymers are summarized in Figure 4.  
In polysaccharide coating and coating with copolymers, the resulted particles are found as 
uniformly encapsulated cores. In another coating approach, polymer molecules anchored  
to the magnetic particle surface resulting in a brush like structure. Liposome and micelle 
forming molecules results a core shell structure with magnetic particles in the core.  
These structures can be used in drug encapsulation with retaining hydrophobic regions. 
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Figure 4. Illustration depicting the assembly of polymers onto the surface of magnetic nanoparticle 
cores (Veiseh et al., 2010). 
Different particles are designed as drug delivery vehicles and a summary of these particles 
are given in Table 1. 
 
Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 Core diameter 
of 10 - 15 nm 
 
Final diameter 
of 160 nm 
chitosan/PAA 
multilayer 
cefradine Layer-by-Layer (LBL) 
 
The drug molecules were 
entrapped inside the hollow 
spheres through diffusion process 
pH responsive Zhang et al., 
2006 
Fe3O4 Final diameter 
of >1 μm 
sodium carboxy 
methyl cellulose 
and chitosan 
------ self-assembly shell composed of 
layers of carboxy methyl cellulose 
and chitosan around the 
magnetic core 
------------ Cui et al., 
2011 
Fe3O4  
 
Core diameter 
of 8 nm 
 
Final diameter 
of of 107 nm 
chitosan cefradine cross-linking the particles with 
glutaraldehyde and the drug is 
embedded in the polymer matrix
 
pH responsive Li et al., 2007 
Fe3O4 Core diameter 
of 5 nm  
 
Final diameter 
of 1–1.5cm 
Alginate / chitosan insulin insulin encapsulation in 
alginate/chitosan beads. The 
beads containing insulin were 
prepared in triplicate by 
extrusion method. 
Magnetic field Finotelli et 
al., 2010 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 Final diameter 
of 200 nm 
multiwalled 
carbon nanotubes 
(MWNTs) 
doxorubic
in 
The MWNT-hybrid 
nanocomposites provided an 
efficient way for the extraction 
and enrichment of doxorubicin 
via pi–pi stacking of DOX 
molecules onto the polyaromatic 
surface of MWNTs. 
pH responsive Shen et al., 
2011 
Fe3O4 Core diameter 
of 3 nm 
CNTs --------- Magnetic nanoparticles adsorb on 
the CNT ends 
------ Panczyk et 
al., 2010 
Fe3O4 Core diameter 
of 5–10 nm. 
 
CNTs average 
diameter 
of about 30–50 
nm and 
average 
length of 
about 100– 
500 nm 
CdTe QDs and 
CNTs 
------- CNT-SPIO-CdTe nanohybrids via 
LBL assembly 
 
---------- Chen et al., 
2010 
γ-Fe2O3 Core diameter 
of 10 nm 
CNT  Diaminop
henothiazi
ne 
(methylen
e blue) 
monodisperse, inherently open-
ended, multi-wall CNTs loaded 
with magnetic iron-based 
nanoparticles that are 
encapsulated within the tube 
graphitic walls 
 Vermisoglou 
et al., 2011 
Fe3O4  Core diameter 
of 8–12 nm 
 
mACs had a 
mean 
diameter of 
about 30 nm 
MWNTs= 
40-60 nm 
(mMWNTs) and 
magnetic-
activated carbon 
particles 
(mACs) 
gemcitabi
ne (GEM) 
Fe3O4 nanoparticles are on the 
outer surface of the PAA 
functionalized MWNTs and the 
drug is adsorbed on the surface . 
 Yang et al., 
2011 
CoFe2O4 
nanoparticles 
Core diameter 
of 6 nm 
 
MWCNTs 
with an outer 
diameter of 
10–30 nm and 
an average 
length of 0.5–2 
μm 
MWCNT/cobalt 
ferrite (CoFe2O4) 
magnetic hybrids 
doxorubic
in  
cobalt ferrite is on the outer 
surface of the MWCNT 
 
pH responsive Wu et al., 
2011 
γ-Fe203 Core diameter 
of 5 nm 
 
Final diameter 
of 100 nm 
DNA fluorescein Single-stranded DNA was 
immobilized onto the silica 
network, and the magnetic 
particles are loaded onto the 
network. The complementary 
DNA sequence was then  
attached to magnetic 
nanoparticles. 
Temperature 
responsive 
Ruiz-
Hernandez 
et al., 2011 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 Core diameter 
of of 8 nm 
 
Final diameter 
of 150 nm 
PEG-
functionalized 
porous silica shell 
doxorubi-
cin 
DOZ conjugated magnetite 
particles are coated with silica to 
obtain core/shell nanoparticles 
and the whole composite is 
coated with PEG 
the breaking of 
the bonding of 
the drug to the 
carrier or 
the swelling 
and 
degradation of 
the polymer.  
Chen et al., 
2010 
α-Fe2O3 Core diameter 
of 13 nm 
 
micron-sized 
mesoporous 
molecular 
sieves (with 
2.9-nm pores) 
MCM-41 and 
MCM-48 
powders gave 
mean pore 
sizes of 3.7 
and 3.5 nm, a 
size between 
1 and 4 µm. 
 
and hollow 
silica 
microcapsules 
(pores of 2.7, 
average 
diameter 
being around 
3 µm. and 15 
nm. 250-nm 
wall thickness
hollow silica 
microcapsules 
--------- Magnetic particles are 
encapsulated inside the hollow 
silica microcapsules 
------------ Arruebo et 
al., 2006 
Fe3O4 Core diameter 
of 10 nm 
 
Final diameter 
of 100 nm 
with 20 nm 
silica shell 
SiO2@ Fe3O4 core–
shell NPs 
 Silica-magnetite nanocomposites 
are emulsified and self-assembly 
of magnetic-mesoporous 
heteronanorods 
at the interface of water-in-oil 
droplets takes place. 
 Zhang et al., 
2011 
Fe3O4  Particles 
between 
150nm and 
4.5 μm 
silica,arabic acid 
and cross-linked 
polysaccharide 
antibody particles with starch derivative or 
polymeric arabic acid as matrix 
material functionalized with an 
antibody 
--- Sieben et al., 
2001 
Fe3O4 Final diameter 
if 202 nm 
 
β-cyclodextrin and 
pluronic polymer 
(F-127)  
curcumin multi-layer polymer coating 
around the magnetic particle and 
the drug is encapsulated via 
diffusion into polymer matrix 
 
The initial 
burst of release 
was due to 
immediate 
dissociation of 
surface bound 
curcumin 
molecules that 
Yallapu et 
al., 2011 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
exist on the CD 
or F127 
polymer 
matrix. The 
remaining 
sustained drug 
release was due 
to the slow 
release of the 
drug entrapped 
inside CD 
and/or F127 
polymer 
layers. 
Fe3O4 Core diameter 
of 14.8 nm  
2-hydroxypropyl-
cyclodextrin 
(HCD) 
onto the gum 
arabic modified 
magnetic 
nanoparticles 
(GAMNP) 
ketoprofe
n 
polymers grafted onto magnetic 
particles(Multilayer polymer 
matrix) 
drug molecules 
are rapidly 
released from 
HCDGAMNP, 
whereas some 
remains 
associated to 
degredation of 
HCD-GAMNP 
Banerjee & 
Chen, 2009 
Fe3O4 Final diameter 
of 
13 nm. 
(3-aminopropyl) 
triethoxysilane 
coated (APTES-
MNPs) with b-
cyclodextrin (β-
CD). 
------- layer-by-layer 
 
--------- Cao et al., 
2009 
Fe3O4 Core diameter 
of 9.2 nm 
Oleic acid, sodium 
dodecyl benzene 
sulfonate SDBS, 
bovine serum 
albumin (BSA) 
--- Oleic acid capped magnetic 
nanoparticles are embedded in 
the SDBS micelle and BSA 
adsorbs onto the micellar entity.  
---- Yang et al., 
2009 
Fe3O4 Final diameter 
of 300 nm  
poly 
(N-
isopropylacrylami
de) PNIPAAm 
and poly(D,L-
lactide-co-
glycolide) PLGA 
Bovine 
serum 
albumin 
(BSA) and 
curcumin 
 
(MLNPs) with a magnetic core 
and two shells made up of 
temperature-sensitive polymers 
(PNIPAAm) were encapsulated 
with PLGA. BSA was first loaded 
into PNIPAAm magnetic 
nanoparticles. Second, curcumin 
was loaded to PLGA to form the 
multilayer nanoparticles 
Temperature 
responsive  
Koppolu et 
al., 2010 
Fe3O4  Final diameter 
of 150 nm  
dextran fluorescei
n (Fluo) or 
TEXAS 
RED® 
(Texas) 
fluorescent 
dye 
By oxidizing Ferumoxides (FE) 
(suspension consisting of 
dextran- coated SPION) 
hydroxyl groups on the dextran 
coating are oxidized to aldehyde 
groups. Lysine fixable fluorescein 
(Fluo) or TEXAS RED® (Texas) 
fluorescent dye (supplied as 
lysine fixable dextran conjugates) 
was reacted with aldehyde FE 
and the fluorescent dye is 
conjugated to FE SPION (FL FE).
---- Lee et al., 
2008 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4  Core diameter 
of 5 5 nm  
 
Final diameter 
of 4 µm, 
 
Fe3O4/
PAH 
 
 
fluorescei
n 
isothiocya
nate 
(FITC)-
Dextran 
layer-by-layer (LbL) assembly
 
FITC-dextran nanoparticle is 
coated with PSS polyelectrolyte 
which contains the magnetic 
particles forming a magnetic shell 
around the particle.
Magnetic field Hu et al., 
2008 
Fe3O4  Core diameter 
of 12 nm 
coated with starch, 
dextran, PEG or 
MPEG
---- Polymeric networks cover a large 
number of continuous magnetic 
monodomains.
---- Huong et al., 
2009 
magnetic 
fluids 
 
Carboxyde-
xtran coated 
DDM128 P6 
(dextran–
magnetite) 
 
Aminosilane 
coated 
(aminosilane–
magnetite) 
MFL AS 
DDM128 P6: 
core diameter 
of 3 nm 
 
MFL AS: core 
diameter of 15 
nm. 
dextran- or
aminosilane-
coated 
---- ----- Jordan et al., 
2006 
Fe3O4 Core diameter 
of 7 nm 
PVA and starch PVA coated particles as large 
clusters where starch coated ones 
are be densely dispersed in the 
polymeric matrix
Voit et al., 
2001 
Fe3O4 Final diameter 
of 110±22 nm
starch ------ Core-shell particles ----- Chertok et 
al., 2008 
Fe3O4 
 
coated with 
starch (G100) 
particles final 
diameter of 
110 (±22) nm 
 
gumarabic 
polysaccha-
ride 
Matrix (Gara) 
particles final 
diameter of 
189nm 
 
Final diameter
225 nm after 
PEI addition
Polyethyleneimine 
(PEI) 
-------- Surface modification of carboxyl-
bearing Gara nano particles with 
PEI  
-------- Chertok et 
al., 2010 
Fe3O4 Final diameter 
of (140- 
190 nm) 
 
Aminated, cross-
linked starch and 
aminosilane 
coated Fe3O4 
modified with 
PEG 
 To ensure that cross-linked starch 
particles was functionally similar 
to aminosilane coated particles, 
starch particles were covalently 
strengthened and aminated with 
concentrated ammonia to form 
aminated-precursor (DN). PEG is 
then linked to aminated 
precursors, DN and aminosilane 
particles with N-
Hydroxysuccinimide (NHS) 
chemistry. 
 Cole et al., 
2011 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 Core diameter 
of 4-10 nm 
PVA and PVA 
with partially 
exchanged 
carboxyl groups.  
----   ----- Lee et al., 
1996 
Fe3O4 Core diameter 
of 10 nm 
PVA matrix --- the films of 200 mm depth and 
different concentrations of iron 
oxide particles in the PVA matrix.
---- Novakova et 
al., 2003 
Fe3O4 Core diameter 
of 
5–10 nm 
 
Final diameter 
of 108-155 nm
PVA ---- core-shell, all iron-oxide particles 
surrounded by a layer of PVA 
polymer. 
---- Qui & 
Winnik, 2000 
γ-Fe203 Core diameter 
of 14, 19 and 
43 nm 
 
Final particles 
are of 
diameter 43 
nm 
PNIPAM doxorubic
in 
MNP cluster is coated with 
PNIPAM and the nanoparticl is 
dehydrated. Core shell 
morphology is achieved with 
dispersion free-radical 
polymerization 
Thermorespon
sive 
Purushotha
m et al., 2009 
Fe3O4 core diameter 
of 13 nm 
PNIPAM doxorubic
in 
Core shell morphology by 
dispersion polymerization where 
drug loaded PNIPAM shell 
contains magnetite clusters. 
Thermorespon
sive 
Purushotha
m et al., 2010 
Fe3O4 Core diameter 
of 11.21 nm 
 
Final particles 
are of 
diameter less 
than 250 μm  
PMMA fluorescei
n 
isothiocya
nate 
(FITC) 
 Thermorespon
sive 
Urbina et al., 
2008 
γ-Fe203  Core diameter 
of 20 nm  
Final particles 
are of 
diameter 400 
nm  
carbon doxorubic
in 
Drug is released form the surface 
of on-coated or partially coated 
magnetic particles 
released from 
the surface of 
our particles at 
a slow 
rate via 
desorption 
Ibarra et al., 
2007 
Fe3O4 Final particles 
are of 
diameter ~10–
20 nm 
poly[aniline-co-
sodium N-(1-
onebutyric 
acid)] aniline 
(SPAnNa) 
1,3-bis(2-
chloroeth
yl)-1- 
nitrosoure
a 
Microcapsule nanoparticles are 
encapsulated during the 
aggregation, forming the 
Fe3O4/SPAnH nanoparticles 
Ultrasound 
and externally 
applied 
magnetic field. 
Chen et al., 
2010 
Fe3O4  Core diameter 
of 8 nm 
 
Final particles 
of diameter 
5.2 µm  
PEs: poly(styrene 
sulfonate) 
(PSS, Mw~70000) 
and 
poly(allylamine 
hydrochloride) 
(PAH, 
Mw~50000). 
 Melamine formaldehyde 
microparticle is coated with 
polyelectrolytes (PE) in a layer-
by-layer (LbL) assembly by 
solvent controlled precipitation 
of PE. The core is then  
dissolved and nanoparticles  
are infiltrated into the capsule 
core. 
 Gaponik et 
al., 2004 
Fe3O4 Final particle 
diameter of 
300–1300 nm  
polystyrene  
 
 Similar technique to 
abovementioned method. 
 Madani et 
al., 2011 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 Core diameter 
of 13 nm  
 
Final particle 
diameter of 3 
μm 
 
 
poly(sodium 4-
styrenesulfonate) 
(PSS) and 
poly(allylamine 
hydrochloride) 
(PAH) 
 
 
Dye  Similar technique to 
abovementioned method. 
 
Magnetic 
heating 
Katagiri et 
al., 2010 
Fe3O4 Core diameter 
of 20 nm 
 
Final particle 
diameter of 
2.82 μm 
(PDDA/PSS)2/PD
DA 
 
Dye  Similar technique to 
abovementioned method. 
Magnetic 
heating 
Katagiri et 
al., 2011 
Fe3O4 and  
γ-Fe203 
Fe3O4 and  
γ-Fe203 core 
diameters of 
9.5 and 4.3 
nm, 
respectively 
Ca alginate beads ----- The nanoparticles were 
entrapped in Ca alginate beads, 
“egg-box like” structure of Ca 
alginate 
------- Finotelli et 
al., 2005 
Fe3O4 Particle 
diameter of 58 
nm 
NP aggragates in 
humic acid (HA) 
--- HA adsorbs onto magnetite 
particles  
------ Hu et al., 
2010 
Fe3O4 Final particle 
diameter of 
7.5 nm  
amino silane( 3-
aminopropyl 
triethoxysilane) 
--- nearly monolayer coating of 
amino silane on the magnetite 
particle surface  
--- Ma et al., 
2003 
Fe3O4 Core particle 
diameter of 
10–15 nm  
Final particle 
diameter of 
400±80 nm 
 
poly-L-lysine 
hydrochloride 
(PLL), poly-L-
glutamic acid 
(PGA) 
DNA layer-by-layer (LbL) assembly on 
polycarbonate templates with 
subsequent removal of these 
templates. 
In the inner surface of 
polycarbonate templates, first 
poly-L-lysine hydrochloride 
(PLL) and poly-L-glutamic acid 
(PGA) are absorbed linking by 
electrostatic interactions as a 
polyelectrolyte layer. Then, multi 
polyelectrolyte layers are 
assembled on polycarbonate 
membrane and Fe3O4 
nanoparticles are linked to PLL 
layer as Fe3O4/PLL bilayers.  
----------- He et al., 
2008 
γ-Fe203 Core 
diameters of 
12 nm. 
 
Final particle 
diameter of 35 
nm (PEI) and 
46 nm (PEI 
plus PEO-
PGA) 
Poly(ethylene 
imine) and 
Poly(ethylene 
oxide)-block-
poly(glutamic 
acid) 
--- MNPs stabilized with polymers 
in two layer-by-layer deposition 
steps. 
---- Thunemann 
et al., 2006 
Fe3O4 Core diameter 
of 12 nm  
aminosilane 
coating 
--- ---- --- Maier-Hauff 
et al., 2011 
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Type of 
magnetic 
nanoparticle 
Particle size Coating agent Drug Design matrix 
Drug release 
mechanism 
Ref 
Fe3O4 and  
γ-Fe203 
Core 
diameters of 
10 nm 
 
Final particle 
diameter of 96 
±15 nm 
poly(ethylene 
glycol) (PEG) 
doxorubic
in  
one-pot synthesis of colloids of 
SPION-DOX-PEG particles, PEG 
shell reduces the access of 
cellular enzymes to the drug-
particle linkage and thus limits 
and/or delays the anticancer 
effect.  
specific 
release 
mechanism for 
drug delivery is 
enzymatic 
cleavage, 
however 
the PEG shell 
seems to reduce 
the access of 
cellular 
enzymes to the 
drug-particle 
linkage and 
thus limits 
and/or delays 
the anticancer 
effect. 
Shkilnyy et 
al., 2010 
Table 1. Summary of magnetic nanomaterials used in drug delivery. 
5. Conclusion 
In this review, uses of magnetic nanoparticles in drug delivery are summarized. Magnetic 
nanoparticles gained a lot of interest due to their biocompatibility, low toxicity and their 
ability to be manipulated upon application of a magnetic field. These special properties 
allow them to be utilized as drug carrier vehicles, either by direct attachment of the drug 
onto the particle or often by using a natural or synthetic polymer to aid carry the drug and 
embedding the magnetic particles in the polymer matrix. Several types of drugs and 
coatings have been explored as drug carriers and a very limited selection is summarized in 
Table 1. The ease of surface modification of these particles opens the opportunity for 
targeting moieties to be attached onto particle surface, facilitating the targeting. Targeting 
with magnetic nanoparticles is predominantly carried out upon application of an external 
magnetic field, which act as an external force to localize the particles in the desired areas in 
the body. Applying an alternating magnetic field to magnetic particles once they are in the 
vicinity of a tumor, results in the temperature of the medium to rise up to 42 oC, which is the 
temperature required for hyperthermia, a complementary treatment along with 
chemotherapy and radiotherapy. We believe that these fascinating particles will find further 
potential applications along with more success in the present ones in the very near future. 
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